P/E ratio for Cytokinetics (CYTK)
P/E ratio as of April 2024 (TTM): -11.7
According to Cytokinetics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.7434. At the end of 2022 the company had a P/E ratio of -10.8.
P/E ratio history for Cytokinetics from 2004 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -10.8 | -33.06% |
| 2021 | -16.1 | 55.79% |
| 2020 | -10.3 | 105.6% |
| 2019 | -5.03 | 55.15% |
| 2018 | -3.24 | 2.2% |
| 2017 | -3.17 | -109.92% |
| 2016 | 32.0 | -396.51% |
| 2015 | -10.8 | -42.11% |
| 2014 | -18.6 | 281.16% |
| 2013 | -4.89 | 196.19% |
| 2012 | -1.65 | 24.9% |
| 2011 | -1.32 | -50.7% |
| 2010 | -2.68 | -137.75% |
| 2009 | 7.10 | -383.9% |
| 2008 | -2.50 | -45.56% |
| 2007 | -4.59 | -4.23% |
| 2006 | -4.79 | 8.84% |
| 2005 | -4.41 | 61.6% |
| 2004 | -2.73 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Amgen AMGN | 19.3 | -264.30% | 🇺🇸 USA |
 Trevena TRVN | -0.0850 | -99.28% | 🇺🇸 USA |
 Ligand Pharmaceuticals LGND | 45.2 | -485.09% | 🇺🇸 USA |
 Acorda Therapeutics
ACOR | -0.0676 | -99.42% | 🇺🇸 USA |
 Array Technologies ARRY | 24.0 | -304.20% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.